Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan's Kirin, Kyowa Merge To Strengthen Biotechnology Focus

This article was originally published in PharmAsia News

Executive Summary

Kirin Holdings and Kyowa Hakko will seek to bring together each company's strength in biotech to create a global research and development-centered Japanese drug company. The two Tokyo-based companies announced a merger agreement Oct. 22, reflecting the ongoing consolidation of the Japanese drug industry

You may also be interested in...



Kirin Pharma Exec Tamao Watanabe On U.S. Biotech-Japan Pharma Collaborations: An Interview With PharmAsia News (Part 2 of 2)

Painstaking communication efforts, including putting plans in writing to overcome a language gap, are keys to Kirin’s partnership with Argos.

Kirin Pharma Exec Tamao Watanabe On U.S. Biotech-Japan Pharma Collaborations: An Interview With PharmAsia News (Part 2 of 2)

Painstaking communication efforts, including putting plans in writing to overcome a language gap, are keys to Kirin’s partnership with Argos.

Kirin Pharma Exec Tamao Watanabe On U.S. Biotech-Japan Pharma Collaborations: An Interview with PharmAsia News (Part 2 of 2)

Tokyo-based Kirin Pharma, which plans to merge with Kyowa Hakko Oct. 1, has done some 35 partnerships since parent company Kirin Brewery entered the pharmaceutical business in 1982. Tamao Watanabe, Kirin Pharma's senior manager of business development for the licensing section in the business development department, recently sat down with PharmAsia News' Tokyo bureau to talk about its partnership with North Carolina-based biotech venture Argos Therapeutics and how to make Japan-Western biotech partnerships work.

Related Content

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel